Jason H Gill Selected Research

Urinary Bladder Neoplasms (Bladder Cancer)

1/2013	Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.
10/2004	NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
5/2004	Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason H Gill Research Topics

Disease

15	Neoplasms (Cancer) 10/2019 - 06/2003
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2013 - 05/2004
2	Neoplasm Metastasis (Metastasis) 01/2017 - 04/2005
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2016 - 11/2004
2	Necrosis 02/2014 - 09/2010
2	Transitional Cell Carcinoma 01/2013 - 04/2005
2	Colonic Neoplasms (Colon Cancer) 11/2004 - 06/2003
1	Infections 05/2020
1	Glioma (Gliomas) 01/2017
1	Breast Neoplasms (Breast Cancer) 02/2014
1	Carcinogenesis 04/2005
1	Obesity 12/2004
1	Lung Neoplasms (Lung Cancer) 11/2004
1	Adenocarcinoma 06/2003

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 05/2020 - 06/2003
5	ProdrugsIBA 01/2017 - 11/2004
4	Proteins (Proteins, Gene)FDA Link 04/2005 - 06/2003
3	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 11/2004
2	Histone Deacetylase InhibitorsIBA 12/2016 - 10/2012
2	ICT2588IBA 04/2014 - 09/2010
2	Membrane-Associated Matrix MetalloproteinasesIBA 02/2014 - 09/2010
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2013 - 06/2003
2	ParaffinIBA 10/2004 - 05/2004
1	AnthracyclinesIBA 01/2019
1	Vorinostat FDA Link 12/2016
1	Indicators and Reagents (Reagents)IBA 04/2014
1	von Willebrand FactorIBA 04/2014
1	Peptides (Polypeptides)IBA 04/2014
1	EnzymesIBA 02/2014
1	Ferrosoferric Oxide (Magnetite)FDA Link 02/2014
1	DuocarmycinsIBA 01/2013
1	Cytotoxins (Cytolysins)IBA 01/2013
1	(1- (chloromethyl)- 1,2- dihydropyrrolo(3,2- e)indol- 3(6H)- yl)(5- methoxy- 1H- indol- 2- yl)methanoneIBA 01/2013
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 01/2013
1	Oxygen (Dioxygen)IBA 09/2010
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2010
1	ICT 2552IBA 09/2010
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2010
1	SodiumIBA 03/2008
1	Phosphates (Orthophosphate)IBA 03/2008
1	pancratistatinIBA 03/2008
1	PPAR gammaIBA 12/2004
1	Liposomes (Liposome)IBA 11/2004
1	Secretory Phospholipases A2IBA 11/2004
1	quinone (benzoquinone)IBA 10/2004
1	NAD (NADH)IBA 10/2004
1	DNA (Deoxyribonucleic Acid)IBA 10/2004
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 10/2004
1	Formaldehyde (Formol)FDA Link 10/2004
1	Oxidoreductases (Dehydrogenase)IBA 05/2004

Therapy/Procedure

6	Therapeutics 10/2019 - 10/2004
1	Drug Therapy (Chemotherapy) 01/2019
1	Radiotherapy 01/2019
1	Intravenous Administration 02/2014
1	Precision Medicine 02/2014